Top Ten most popular articles on Pharmafile.com this week!
pharmafile | January 11, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, Bristol-Myers Squibb, Shire, Takeda, bristol myers squibb, death row, pharma, top 10
With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger merger was announced as US firm Bristol-Myers Squibb revealed that it would acquire Celgene in a deal worth $74 million. The news came after analysts suggested that $400 billion worth of M&A deals were expected for 2019.
Meanwhile the Anglo-Swedish multinational AstraZenca lost to senior execs to biotech firms later announcing the appointment of controve3rsial cancer doc José Baselga as the head of its new formed cancer R&D unit. For news and more check out this week’s top ten most popular stories at Pharmafile.com!
10. Death row inmate whose execution was postponed found dead in cell
Scott Dozier, the death row inmate whose execution was stalled by court cases launched by pharmaceutical companies, has been found dead in his cell.
9. $400 billion in healthcare M&A deals expected for 2019
The coming year is set to see mergers and acquisitions in the healthcare sector worth more than $400 billion, according to multinational law firm Baker McKenzie.
8. Takeda completes Shire acquisition
Japanese firm Takeda Pharmaceuticals has successfully completed its acquisition of Shire Plc. The long anticipated deal has propelled the firm into the top ten biggest pharmaceutical companies worldwide.
7. AstraZeneca loses two senior executives as biotechs appoint new CEOs
Two of AstraZeneca’s senior executives have been poached by the biotech firms Ironwood Pharmaceuticals and Immunocore, as the two biotechnology companies announced the appointment of their new CEOs.
6. Roche’s Genentech inks potential $2bn personalised cancer drug development deal
Roche’s Genentech is set to enter into a deal with Adaptive Biotechnologies to bolster its pursuits in the treatment of cancer, paying $300 million upfront in a new deal to manufacture and develop novel neoantigen directed T-cell therapies for various forms of the disease.
5. BMS to acquire Celgene for $74 billion in biggest-ever pharma deal
Starting off 2019 with a bang, Bristol-Myers Squibb has announced its intention to acquire fellow drugmaker Celgene as part of an agreement which, valued at approximately $74 billion, would be the largest pharmaceutical deal ever, eclipsing Bayer and Monsanto’s $63 billion merger in 2016.
4. AbbVie records an estimated $4billion in impairment charges after failure of cancer drug Rova-T
US firm AbbVie has said that it will record an estimated $4 billion in impairment charges related to the abandonment of the company’s once much anticipated investigational cancer treatment Rova-T.
3. NICE rejects Novartis’ Aimovig migraine injection for NHS use
It’s disappointing news for Novartis as NICE revealed that it had decided not to recommend Aimovig (erenumab) for routine NHS use for the prevention of chronic and episodic migraine in patients across England and Wales.
2. AstraZeneca hire controversial cancer doc to head new Oncology R&D unit
The Anglo-Swedish multinational AstraZeneca has named Dr José Baselga as the firm’s new head of research and development in oncology.
1. Pfizer to shutter two manufacturing plants in India, 1,700 jobs at risk
Pfizer has announced it is to shut down two of its manufacturing facilities in India – a move which could affect more than 1,700 employees working across the two sites.
Related Content
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …
